HUTCHMED (China) Ltd
HCM
Company Profile
Business description
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
Contact
2 Queen's Road Central
48th Floor, Cheung Kong Center
Hong Kong
HKGT: +852 2121 8200
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
1,811
Stocks News & Analysis
stocks
Another incredible quarter from Microsoft
We were wrong when we thought last quarter would be hard to top.
stocks
10 best US dividend aristocrats to buy now—including a surprise outperformer
These undervalued stocks with wide and narrow moats have increased their dividends for 25 consecutive years or more.
stocks
Leading ASX players in this field look materially overvalued
We raise our Fair Value estimates but still think that current share prices rely on overly optimistic expectations.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,917.10 | 81.90 | -0.91% |
| CAC 40 | 7,546.16 | 225.81 | -2.91% |
| DAX 40 | 23,425.97 | 639.50 | -2.66% |
| Dow JONES (US) | 43,600.72 | 530.26 | -1.20% |
| FTSE 100 | 9,068.58 | 64.23 | -0.70% |
| HKSE | 24,507.81 | 265.52 | -1.07% |
| NASDAQ | 20,664.08 | 458.37 | -2.17% |
| Nikkei 225 | 40,799.60 | 270.22 | -0.66% |
| NZX 50 Index | 12,729.40 | 94.34 | -0.74% |
| S&P 500 | 6,239.57 | 99.82 | -1.57% |
| S&P/ASX 200 | 8,662.00 | 80.80 | -0.92% |
| SSE Composite Index | 3,559.95 | 13.26 | -0.37% |